ClinicalTrials.gg
CompletedNCT01377194Updated Oct 29, 2013Results posted

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran ER and Levomilnacipran ER in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 51 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
568
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
5th of 14
568 · median 472
Started
2011
with 1 other
Phase 3
10 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 10 in phase 3, and was the 7th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-75 years old
  • Currently meet the criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 6 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with who are not practicing a reliable method of .
  • Patients who are considered a suicide risk
  • Patients with a history of meeting criteria for
  • a. any manic or hypomanic episode
  • b. schizophrenia or any other psychotic disorder
  • c. obsessive-compulsive disorder.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
568 participants (actual)

Study arms

  • Experimental
    1

    40mg Levomilnacipran ER

    Drug: Levomilnacipran ER

  • Experimental
    2

    80mg of Levomilnacipran ER

    Drug: Levomilnacipran ER

  • Placebo comparator
    3

    Placebo

    Drug: Placebo

Interventions

  • Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks

  • Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks

  • DrugPlacebo

    Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.

    The Montgomery-Asberg Depression Rating Scale (MADRS) rates patients on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item was scored on a 7-point scale. A score of 0 indicated the absence of symptoms, and a score of 6 indicated symptoms of maximum severity. The minimum overall score possible was 0 (absence of symptoms), with a maximum overall score of 60 (maximum severity).

    Time frame: From Baseline to Week 8

Secondary outcomes

  1. Change in Sheehan Disability Scale (SDS) Total Score

    The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

    Time frame: From Baseline to Week 8

07

Results

Posted Oct 29, 2013

Participant flow

Patient recruitment occurred during a 6 month period from June to December 2011 at 47 study sites in the United States and 4 study sites in Canada.

Participant flow — Overall Study
MilestonePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mg
Started186188188
Completed154145142
Not completed324346
Withdrew: Adverse event31219
Withdrew: Lack of efficacy333
Withdrew: Protocol violation4106
Withdrew: Withdrawal by subject8107
Withdrew: Lost to follow-up14811

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.

The Montgomery-Asberg Depression Rating Scale (MADRS) rates patients on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item was scored on a 7-point scale. A score of 0 indicated the absence of symptoms, and a score of 6 indicated symptoms of maximum severity. The minimum overall score possible was 0 (absence of symptoms), with a maximum overall score of 60 (maximum severity).

Time frame:
From Baseline to Week 8
Reported as:
Mean · Units on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
Units on a scalePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mg
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.-11.3 ± 0.77-14.6 ± 0.79-14.4 ± 0.79
Statistical analysis
  • Placebo vs Levomilnacipran ER 40 mg · mixed-model for repeated measures · p = 0.0027 · Least squares mean difference: -3.303 · 95% CI -5.457 to -1.148
  • Placebo vs Levomilnacipran ER 80 mg · mixed-model for repeated measures · p = 0.0043 · Least squares mean difference: -3.141 · 95% CI -5.293 to -0.988
SecondaryChange in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Change in Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mg
Change in Sheehan Disability Scale (SDS) Total Score-5.4 ± 0.66-7.3 ± 0.68-8.2 ± 0.66
Statistical analysis
  • Placebo vs Levomilnacipran ER 40 mg · Mixed Models Analysis · p = 0.0459 · Least squares mean difference: -1.827 · 95% CI -3.620 to -0.033Mixed-effects model for repeated measures.
  • Placebo vs Levomilnacipran ER 80 mg · Mixed Models Analysis · p = 0.0028 · Least squares mean difference: -2.720 · 95% CI -4.494 to -0.946Mixed-effects model for repeated measures.

Adverse events

Collected over Adverse event data was collected over a 10 month period from June 2011 to March 2012.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/186 (0.5%)58/186 (31.2%)
Levomilnacipran ER 40 mg—3/188 (1.6%)90/188 (47.9%)
Levomilnacipran 80 mg—0/188 (0%)110/188 (58.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mg
Facial Bones FractureInjury, poisoning and procedural complications1/1860/1880/188
Road traffic accidentInjury, poisoning and procedural complications1/1860/1880/188
Non-cardiac chest painGeneral disorders0/1861/1880/188
IntussusceptionGastrointestinal disorders0/1861/1880/188
AsthmaRespiratory, thoracic and mediastinal disorders0/1861/1880/188
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mg
NauseaGastrointestinal disorders11/18627/18829/188
Erectile dysfunctionReproductive system and breast disorders1/704/719/64
HeadacheNervous system disorders16/18622/18825/188
Dry mouthGastrointestinal disorders7/18619/18818/188
HyperhidrosisSkin and subcutaneous tissue disorders6/1864/18815/188
TachycardiaCardiac disorders6/1864/18815/188
Testicular painReproductive system and breast disorders0/703/715/64
ConstipationGastrointestinal disorders4/18613/18812/188
Heart rate increasedInvestigations0/18613/18811/188
DizzinessNervous system disorders1/1867/18812/188

Baseline characteristics

The Baseline Participant population is based on the 562 randomized patients who went on to receive double-blind treatment (Safety Population).

Age Continuous
Age Continuous(years)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
Mean42.3 ± 13.242.9 ± 13.443.1 ± 12.842.8 ± 13.1
Age, Customized
Age, Customized(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
< 203159
≥ 20-2935352898
≥ 30-39434044127
≥ 40-49454953147
≥ 50-59434236121
≥ 6017212260
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
Female116117124357
Male707164205
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
White135142139416
Black or African-American353736108
Asian74314
American Indian of Alaska Native3003
Native Hawaiian or other Pacific Islander1001
Other Race551020
Hispanic23241562
Non-Hispanic163164173500
Region of Enrollment
Region of Enrollment(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
United States177183180540
Canada95822
Weight
Weight(kg)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
Mean81.60 ± 17.7781.35 ± 17.0981.73 ± 17.5781.56 ± 17.45
Height
Height(cm)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
Mean168.41 ± 9.69169.48 ± 9.79168.63 ± 8.91168.84 ± 9.47
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms Per Meter Squared)PlaceboLevomilnacipran ER 40 mgLevomilnacipran 80 mgTotal
Mean28.67 ± 5.1928.25 ± 5.1728.71 ± 5.6828.54 ± 5.35
08

Study locations

51 sites
  • Forest Investigative Site 039
    Birmingham, Alabama 35216, United States
  • Forest Investigative Site 037
    Beverly Hills, California 90210, United States
  • Forest Investigative Site 012
    Encino, California 91316, United States
  • Forest Investigative Site 038
    Newport Beach, California 92660, United States
  • Forest Investigative Site 024
    Oceanside, California 92056, United States
  • Forest Investigative Site 001
    Redlands, California 92374, United States
  • Forest Investigative Site 031
    San Diego, California 92108, United States
  • Forest Investigative Site 050
    Sherman Oaks, California 91403, United States
  • Forest Investigative Site 034
    Cromwell, Connecticut 06416, United States
  • Forest Investigative Site 021
    Coral Springs, Florida 33067, United States
  • Forest Investigative Site 043
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site 018
    Gainesville, Florida 32607, United States
  • Forest Investigative Site 060
    Hallandale Beach, Florida 33009, United States
  • Forest Investigative Site 020
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 005
    Ocala, Florida 34471, United States
  • Forest Investigative Site 014
    Orlando, Florida 32806, United States
  • Forest Investigative Site 028
    Orlando, Florida 32806, United States
  • Forest Investigative Site 046
    Atlanta, Georgia 30328, United States
  • Forest Investigative Site 041
    Chicago, Illinois 60634, United States
  • Forest Investigative Site 054
    Chicago, Illinois 60640, United States
  • Forest Investigative Site 026
    Hoffman Estates, Illinois 60169, United States
  • Forest Investigative Site 045
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 056
    Prairie Village, Kansas 66206, United States
  • Forest Investigative Site 049
    Haverhill, Massachusetts 01830, United States
  • Forest Investigative Site 044
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 023
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site 004
    Brooklyn, New York 11214, United States
  • Forest Investigative Site 002
    Mount Kisco, New York 10549, United States
  • Forest Investigative Site 016
    New York City, New York 10003, United States
  • Forest Investigative Site 051
    New York, New York 10021, United States
  • Forest Investigative Site 042
    Orangeburg, New York 10962, United States
  • Forest Investigative Site 061
    Raleigh, North Carolina 27607, United States
  • Forest Investigative Site 010
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 048
    Oklahoma City, Oklahoma 73112, United States
  • Forest Investigative Site 053
    Portland, Oregon 97210, United States
  • Forest Investigative Site 017
    Salem, Oregon 97301, United States
  • Forest Investigative Site 011
    Allentown, Pennsylvania 18104, United States
  • Forest Investigative Site 052
    Bridgeville, Pennsylvania 15017, United States
  • Forest Investigative Site 027
    Philadelphia, Pennsylvania 19107, United States
  • Forest Investigative Site 059
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site 029
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 009
    Dallas, Texas 75231, United States
  • Forest Investigative Site 007
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 035
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 022
    Bellevue, Washington 98007, United States
  • Forest Investigative Site 055
    Seattle, Washington 98104, United States
  • Forest Investigative Site 057
    Spokane, Washington 99204, United States
  • Forest Investigative Site 025
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Forest Investigative Site 036
    Sydney, Nova Scotia B1S 2EB, Canada
  • Forest Investigative Site 006
    Chatham, Ontario N7M 1B7, Canada
  • Forest Investigative Site 003
    Ottawa, Ontario K1G 4G3, Canada
09

References and documents

Publications

  • Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord. 2015 Jun 11;17(3):10.4088/PCC.14m01753. doi: 10.4088/PCC.14m01753. eCollection 2015. PubMed 26644957 ↗
  • Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014 Jan;39(1):40-9. doi: 10.1503/jpn.130040. PubMed 24144196 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 7 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2011
First posted
Jun 21, 2011
Start
Jun 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results delay requested
Apr 27, 2012
Results first posted
Oct 29, 2013
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01377194
Responsible party
Sponsor
First posted
Jun 21, 2011
Start date
Jun 2011
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Oct 29, 2013
Last update
Oct 29, 2013

Study contacts

Carl Gommoll, MS
study director · Forest Research Institute, a subsidiary of Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion